Immunomodulatory Effect of Traditional Chinese Medicine Combined with Systemic Therapy on Patients with Liver Cancer: A Systemic Review and Network Meta-analysis

Peng, Qing; Yu, Lihua; Wang, Xinhui; Yan, Hu; Xie, Yuqing; Jiang, Yuyong; Yang, Zhiyun

doi:10.7150/jca.74829

Cited by 7 publications

(4 citation statements)

References 54 publications

(57 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…At present, the mechanism of this synergy is still unclear. However, in previous studies, it has been reported that Chinese medicine could regulate immune function ( 32 - 34 ). In the primary research, we found that the ratio of the spleen to organ increased after the intervention of Chinese medicine, while since the spleen contains many immune cells, the intervention of Chinese medicine may regulate the immune function.…”

Section: Discussionmentioning

confidence: 99%

Chinese Medicine Enhancing Response Rates to Immunosuppressant PD-L1 Inhibitor and Improving the Quality of Life of Hepatocellular Carcinoma-Bearing Mice

Liu

et al. 2023

Iran J Pharm Res

View full text Add to dashboard Cite

Background: Malignant tumors are a significant disease endangering human health. Chinese Medicine (CM) plays an important role in comprehensive and holistic tumor treatment. Objectives: We aimed to investigate whether CM combined with the immunosuppressant PD-1/PD-L1 inhibitor has a good synergistic effect and can significantly improve response rates for the immunosuppressant. Methods: We combined CM with immunosuppressant in treating six-week-old hepatocellular carcinoma-bearing mice and compared the outcomes of groups undergoing different interventions: blank group, control group, CM group, PD-L1 inhibitor group, and CM + PD-L1 inhibitor group, with ten mice in each group. The quality of life was evaluated along with the tumor inhibition effects and growth rates. Results: CM significantly reduced tumor load and improved the quality of life of cancer-bearing mice. The survival rate was 81.8% in the control group, 100% in the CM group, 90.9% in the PD-L1 inhibitor group, and 100% in the combined group in the first week. The survival rate was 45.5% in the control group, 54.5% in the CM group, 81.8% in the PD-L1 inhibitor group, and 81.8% in the combined group in the second week. 38% mice in the CM+PD-L1 inhibitor group with smaller tumor size than the average of the control group, which was much higher than other treatment groups. CM also reduced the expression of JAK2 mRNA and STAT3 mRNA, although not significantly (P > 0.05), and reduced PD-L1 mRNA in tumor tissue compared to the control group (P < 0.05). Conclusions: CM had a synergistic effect on PD-L1 inhibitors and increased response rates to PD-L1 inhibitor treatment.

show abstract

Section: Discussionmentioning

confidence: 99%

Chinese Medicine Enhancing Response Rates to Immunosuppressant PD-L1 Inhibitor and Improving the Quality of Life of Hepatocellular Carcinoma-Bearing Mice

Liu

et al. 2023

Iran J Pharm Res

View full text Add to dashboard Cite

show abstract

“…KAI, one of the traditional injections of Chinese medicine, exhibits excellent anti-tumor activity and synergistic effects of chemotherapeutic drugs in various solid tumors (Cang et al, 2022;Pu et al, 2022). However, the possible mechanism of KAI in cancer therapy remains obscure.…”

Section: Discussionmentioning

confidence: 99%

Uncovering the mechanism of Kang-ai injection for treating intrahepatic cholangiocarcinoma based on network pharmacology, molecular docking, and in vitro validation

Song

Lu²,

Wang³

et al. 2023

Front. Pharmacol.

View full text Add to dashboard Cite

Objective: Kang-ai injection (KAI) has been a popular adjuvant treatment for solid tumors, but its anti-tumor mechanism in intrahepatic cholangiocarcinoma (ICC) remains poorly understood. This study applied a network pharmacology-based approach to unveil KAI’s anti-tumor activity, key targets, and potential pharmacological mechanism in ICC by integrating molecular docking and in vitro validation.Methods: The KAI-compound-target-ICC network was constructed to depict the connections between active KAI compounds and ICC-related targets based on the available data sources. The crucial ingredients, potential targets, and signaling pathways were screened using GO, KEGG enrichment analysis, and the PPI network. Molecular docking was performed to visualize the interactions between hub targets and components. In vitro experiments were carried out to validate the findings.Results: Among the 87 active components of KAI and 80 KAI-ICC-related targets, bioinformatics analysis identified quercetin as a possible candidate. GO and KEGG enrichment analysis indicated that the PI3K-AKT signaling pathway might be essential in ICC pharmacotherapy. The PPI network and its sub-networks screened 10 core target genes, including AKT1 and IL1β. Molecular docking results showed stable binding between AKT1 and IL1β with KAI active ingredients. The in vitro experiments confirmed that KAI might suppress the proliferation of ICC cell lines by inhibiting the PI3K/AKT signaling pathway, consistent with the network pharmacology approach and molecular docking predictions.Conclusion: The study sheds light on KAI’s biological activity, potential targets, and molecular mechanisms in treating ICC and provides a promising strategy for understanding the scientific basis and therapeutic mechanisms of herbal treatments for ICC. This research has important implications for developing new, targeted therapies for ICC and highlights the importance of network pharmacology-based approaches in investigating complex herbal formulations.

show abstract

“…Patients with hepatocellular carcinoma who receive Huaier can extend their recurrence-free survival and reduce their risk of extrahepatic recurrence (Zhang et al, 2021;Li et al, 2022;Luo and Hu, 2023). In addition, adjuvant therapy with Huaier can significantly improve immune function as well as conventional anticancer therapies' efficacy and safety (Pu et al, 2022). In the treatment of breast cancer, conventional treatment combined with Huaier significantly improved overall remission and the health-related quality of life for patients compared to that obtained via conventional treatment alone (Yao et al, 2020), and Huaier adjuvant therapy has also been shown to improve immunity and enhance sensitivity to radiotherapy (Zhang et al, 2019;Li et al, 2020) (Table 1).…”

Section: The Use Of Huaier In the Clinical Treatment Of Breast Cancermentioning

confidence: 99%

Molecular mechanisms and therapeutic applications of huaier in breast cancer treatment

Luo,

Zhou,

et al. 2024

Front. Pharmacol.

View full text Add to dashboard Cite

Breast cancer is one of the most common female malignant tumors today and represents a serious health risk for women. Although the survival rate and quality of life of patients with breast cancer are improving with the continuous development of medical technology, metastasis, recurrence, and drug resistance of breast cancer remain a significant problem. Huaier, a traditional Chinese medicine (TCM) fungus, is a type of Sophora embolism fungus growing on old Sophora stems. The polysaccharides of Trametes robiniophila Murr (PS-T) are the main active ingredient of Huaier. There is increasing evidence that Huaier has great potential in breast cancer treatment, and its anti-cancer mechanism may be related to a variety of biological activities, such as the inhibition of cell proliferation, metastasis, tumor angiogenesis, the promotion of cancer cell death, and regulation of tumor-specific immunity. There is growing evidence that Huaier may be effective in the clinical treatment of breast cancer. This review systematically summarizes the basic and clinical studies on the use of Huaier in the treatment of breast cancer, providing useful information to guide the clinical application of Huaier and future clinical studies.

show abstract

Immunomodulatory Effect of Traditional Chinese Medicine Combined with Systemic Therapy on Patients with Liver Cancer: A Systemic Review and Network Meta-analysis

Cited by 7 publications

References 54 publications

Chinese Medicine Enhancing Response Rates to Immunosuppressant PD-L1 Inhibitor and Improving the Quality of Life of Hepatocellular Carcinoma-Bearing Mice

Chinese Medicine Enhancing Response Rates to Immunosuppressant PD-L1 Inhibitor and Improving the Quality of Life of Hepatocellular Carcinoma-Bearing Mice

Uncovering the mechanism of Kang-ai injection for treating intrahepatic cholangiocarcinoma based on network pharmacology, molecular docking, and in vitro validation

Molecular mechanisms and therapeutic applications of huaier in breast cancer treatment

Contact Info

Product

Resources

About